Literature DB >> 3735391

Antibody to the gastric campylobacter-like organism ("Campylobacter pyloridis")--clinical correlations and distribution in the normal population.

D M Jones, J Eldridge, A J Fox, P Sethi, P J Whorwell.   

Abstract

Different cellular proteins of the gastric campylobacter-like organism (GCLO) were shown to be immunogenic for man. Antibodies to GCLO were detected in sera by both complement fixation and enzyme-linked immunoabsorbent assay. Antibody was found in 133 (52%) of 254 patients attending for gastroscopy. There was a high correlation between presence of antibody and a positive GCLO culture from the gastric mucus. Patients with normal endoscopic appearances, duodenal ulcer, duodenitis and oesophagitis had similar prevalences (c. 50%) of antibody. Only patients with endoscopically visible gastritis or gastric ulcer had a higher frequency (c. 80%) of antibody. In a normal population, antibody was uncommon in individuals less than 20 years old, but the prevalence of antibody increased (to c. 50%) with age. There was little evidence to support an important pathological role for GCLO in disorders of the upper gastrointestinal tract, although the possibility that it may be a co-factor in the pathogenesis of gastric ulcer cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3735391     DOI: 10.1099/00222615-22-1-57

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  67 in total

1.  Helicobacter pylori: the primary cause of duodenal ulceration or a secondary infection?

Authors:  M Hobsley; F I Tovey
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection?

Authors:  D G Maxton; E D Srivastava; P J Whorwell; D M Jones
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

3.  Helicobacter pylori infection and growth delay in older children.

Authors:  F Perri; M Pastore; G Leandro; R Clemente; Y Ghoos; M Peeters; V Annese; M Quitadamo; A Latiano; P Rutgeerts; A Andriulli
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

4.  Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection.

Authors:  Y Glupczynski; A Burette; H Goossens; C DePrez; J P Butzler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

5.  Evaluation of a commercial ELISA for serodiagnosis of Helicobacter pylori infection.

Authors:  J E Crabtree; T M Shallcross; R V Heatley; J I Wyatt
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

6.  Elevated risk of Helicobacter pylori infection in submarine crews.

Authors:  I Hammermeister; G Janus; F Schamarowski; M Rudolf; E Jacobs; M Kist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 7.  Helicobacter pylori: the African enigma.

Authors:  C Holcombe
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

Review 8.  Precise role of H pylori in duodenal ulceration.

Authors:  Michael Hobsley; Frank I Tovey; John Holton
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

9.  Serological diagnosis of Helicobacter pylori--evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs.

Authors:  A S Taha; J Reid; P Boothmann; C G Gemmell; F D Lee; R D Sturrock; R I Russell
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

10.  Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism.

Authors:  U E Mai; G I Perez-Perez; L M Wahl; S M Wahl; M J Blaser; P D Smith
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.